Sanofi, Regeneron pay $67.5M for a regulatory shortcut in blockbuster PCSK9 race with Amgen

John Carroll

and just stole a march on in the to get their cardio drug through the FDA and onto the market. The two companies revealed Wednesday evening that they had picked up a priority review voucher BioMarin had won for a recent rare disease drug approval, paying $ 67.5 million for the . They'll split the cost and share in the benefit, shaving four months off the regulatory review time for alirocumab.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS